Evaluate
Depends
Confidence: Low
Public evidence is thin, but Evaluate appears to be enterprise pharma market intelligence for strategy, BD, and competitive-intelligence teams with real budgets.
New check
Comparison
Evaluate and ClinicalTrials.gov both land on Depends.
Public evidence is thin, but Evaluate appears to be enterprise pharma market intelligence for strategy, BD, and competitive-intelligence teams with real budgets.
If you sponsor FDA-regulated trials, you have no choice: it is free and legally mandatory.
| Compare | ||
|---|---|---|
| Verdict | Depends | Depends |
| Best for | Pharma BD and strategy teams | Sponsors of FDA-regulated US trials |
| Who it's not for | Small teams and startups . enterprise overkill | Patients wanting simple, guided trial matching . the UX will fight you |
| Privacy | No known public vulnerabilities found in the sources reviewed.² | No known public vulnerabilities found in the sources reviewed. |
| Support quality | No support evidence found. | NLM help desk exists; quality undocumented. |
| Public sentiment | No readable user review text appeared in public snippets, so satisfaction could not be verified.³ | Practitioners treat it as the indispensable canonical registry but consistently complain the search and navigation are painful.15 |
| Biggest gotcha | No public pricing in sources; enterprise contracts can hide seat minimums and renewal hikes.⁴ | FDAAA makes registration and results posting mandatory for applicable US trials; FDA issues violation notices.13 |